✦ LIBER ✦

398 - Treatment of patients with relapsed or refractory acute myelold leukemia (AML) with recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate

✍ Scribed by E.L. Slevers; I.D. Bernstein; R.T. Spielberger; S.J. Forman; K. Shannon-Dorcy; F.R. Appelbaum

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of relapsed or refractory acut

✍ Feldman, E; Kalaycio, M; Weiner, G; Frankel, S; Schulman, P; Schwartzberg, L; Ju 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Phase I/II study of humanized anti-CD33

✍ Yukio Kobayashi; Kensei Tobinai; Akihiro Takeshita; Kensuke Naito; Osamu Asai; N 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 231 KB

Phase III Trial of a Humanized Anti-CD33

✍ Gibson, Angelia D.; Tallman, Martin S.; Jain, Vinay K. 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 87 KB

Phase I studies of AVE9633, an anti-CD33

✍ Simona Lapusan, Maria B. Vidriales, Xavier Thomas, Stephane de Botton, Anne Vekh 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 482 KB